Following infection with [[HIV]]-1, the rate of clinical disease progression varies between individuals. Factors such as host susceptibility, [[genetics]] and [[immune]] function,<ref name=Morgan2002b>{{cite journal |last=Morgan |first=D. |authorlink= |coauthors=C. Mahe, B. Mayanja, J.M. Okongo, R. Lubega and J.A. Whitworth |year=2002 |month= |title=HIV-1 infection in rural Africa: is there a difference in median time to AIDS and survival compared with that in industrialized countries? |journal=AIDS |volume=16 |issue=4 |pages=597–603 |pmid=11873003 |url= |accessdate= |quote= |doi=10.1097/00002030-200203080-00011 }}</ref> [[health care]] and [[co-infection]]s<ref name=Morgan2002a>{{cite journal |last=Morgan |first=D. |authorlink= |coauthors=C. Mahe, B. Mayanja and J.A. Whitworth |year=2002 |month= |title=Progression to symptomatic disease in people infected with HIV-1 in rural Uganda: prospective cohort study |journal=BMJ |volume=324 |issue=7331 |pages=193–196 |issn=11809639 |url= |accessdate= |quote= |pmid=11809639 |pmc=64788 |doi=10.1136/bmj.324.7331.193}}</ref> as well as viral genetic variability<ref name=campbell>{{cite journal |last=Campbell |first=G.R. |authorlink=  |year=2004 |month= |title=The glutamine-rich region of HIV-1 Tat protein involved in T cell apoptosis |journal=Journal of Biological Chemistry |volume=279 |issue=46 |pages=48197–48204 |pmid=15331610 |url= |accessdate= |quote= |doi=10.1074/jbc.M406195200 |display-authors=1 |last2=Pasquier |first2=E |last3=Watkins |first3=J |last4=Bourgarel-Rey |first4=V |last5=Peyrot |first5=V |last6=Esquieu |first6=D |last7=Barbier |first7=P |last8=De Mareuil |first8=J |last9=Braguer |first9=D }}</ref> may affect the rate of progression to the point of needing to take medication in order not to develop [[AIDS]].

==Rapid progressors==
A small percentage of [[HIV]]-infected individuals rapidly progress to [[AIDS]] if they fail to take the medication within four years after primary HIV-[[infection]] and are termed Rapid Progressors (RP).<ref name=Anzala>{{cite journal |last=Anzala |first=O.A. |authorlink= |coauthors=N.J. Nagelkerke, J.J. Bwayo, D. Holton, S. Moses, E.N. Ngugi, J.O. Ndinya-Achola and F.A. Plummer |year=1995 |month= |title=Rapid progression to disease in African sex workers with human immunodeficiency virus type 1 infection |journal=Journal of Infectious Disease |volume=171 |issue=3 |pages=686–689 |pmid=7876618 |url= |accessdate= |quote= |doi=10.1093/infdis/171.3.686 }}</ref> Indeed some individuals have been known to progress to AIDS and death within a year after primo-infection. Rapid progression was originally thought to be continent specific, as some studies reported that [[disease]] progression is more rapid in [[Africa]],<ref name=Anzala/><ref name=N'Galy>{{cite journal |doi=10.1056/NEJM198810273191704 |last=N'Galy |first=B. |authorlink= |coauthors=R.W. Ryder, K. Bila, K. Mwandagalirwa, R.L. Colebunders, H. Francis, J.M. Mann T.C. and Quinn |year=1988 |month= |title=Human immunodeficiency virus infection among employees in an African hospital |journal=New England Journal of Medicine |volume=319 |issue=17 |pages=1123–1127 |pmid=3262826 |url= |accessdate= |quote= }}</ref><ref name=whittle>{{cite journal |last=Whittle |first=H. |authorlink= |coauthors=A. Egboga, J. Todd, T. Corrah, A. Wilkins, E. Demba, G. Morgan, M. Rolfe, N. Berry and R. Tedder |year=1992 |month= |title=Clinical and laboratory predictors of survival in Gambian patients with symptomatic HIV-1 or HIV-1 infection |journal=AIDS |volume=6 |issue=7 |pages=685–689 |pmid=1354448 |url= |accessdate= |quote= |doi=10.1097/00002030-199207000-00011 }}</ref> but others have contested this view.<ref name=Morgan2002b/><ref name=Morgan2002a/><ref name=marlink>{{cite journal |last=Marlink |first=R. |authorlink=  |year=1994 |month= |title=Reduced rate of disease development after HIV-2 infection as compared to HIV-1 |journal=Science |volume=265 |issue=5178 |pages=1587–1590 |pmid=7915856 |url= |accessdate= |quote= |doi=10.1126/science.7915856 |display-authors=1 |last2=Kanki |first2=P |last3=Thior |first3=I |last4=Travers |first4=K |last5=Eisen |first5=G |last6=Siby |first6=T |last7=Traore |first7=I |last8=Hsieh |first8=C. |last9=Dia |first9=M. }}</ref><ref name=french>{{cite journal |last=French |first=N. |authorlink= |coauthors=A. Mujugira, J. Nakiyingi, D. Mulder, E.N. Janoff and C.R. Gilks |year=1999 |month= |title=Immunologic and clinical stages in HIV-1-infected Ugandan adults are comparable and provide no evidence of rapid progression but poor survival with advanced disease |journal=Journal of Acquired Immune Deficiency Syntromes |volume=22 |issue=5 |pages=509–516 |pmid=10961614 |url= |accessdate= |quote= }}</ref>

==Long term non-progressors==
{{Main|Long-term nonprogressor|elite controllers}}
Another subset of individuals who are persistently infected with HIV-1, but show no signs of disease progression for over 12 years and remain asymptomatic are classified as Long Term Non-Progressors (LTNP). In these individuals, it seems that HIV-infection has been halted with regard to disease progression over an extended period of time.<ref name=buchbinder>{{cite journal |last=Buchbinder |first=S.P. |authorlink= |coauthors=M.H. Katz, N.A. Hessol, P.M. O'Malley and S.D. Holmberg |year=1994 |month= |title=Long-term HIV-1 infection without immunologic progression |journal=AIDS |volume=8 |issue=8 |pages=1123–1128 |pmid=7986410 |url= |accessdate= |quote= |doi=10.1097/00002030-199408000-00014 }}</ref><ref name=cao>{{cite journal |last=Cao |first=Y. |authorlink= |coauthors=L. Qin, L. Zhang, J. Safrit and D.D. Ho |year=1995 |month= |title=Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection |journal=New England Journal of Medicine |volume=332 |issue=4 |pages=201–208 |pmid=7808485 |url= |accessdate= |quote= |doi=10.1056/NEJM199501263320401 }}</ref><ref name=easterbrook>{{cite journal |last=Easterbrook |first=P.J. |authorlink= |coauthors= |year=1994 |month= |title=Non-progression in HIV infection |journal=AIDS |volume=8 |issue=8 |pages=1179–1182 |pmid=7832923 |url= |accessdate= |quote= |doi=10.1097/00002030-199408000-00023 }}</ref><ref name=levy>{{cite journal |last=Lévy |first=J.A. |authorlink= |coauthors= |year=1993 |month= |title=HIV pathogenesis and long-term survival |journal=AIDS |volume=7 |issue=11 |pages=1401–1410 |pmid=8280406 |url= |accessdate= |quote= |doi=10.1097/00002030-199311000-00001 }}</ref> However, the term LTNP is a misnomer as that progression towards AIDS can occur even after 15 years of stable infection.<ref name=harrer>{{cite journal |last=Harrer |first=T. |authorlink=  |year=1996 |month= |title=Strong cytotoxic T cell and weak neutralizing antibody responses in a subset of persons with stable nonprogressing HIV type 1 infection |journal=Aids research and Human Retroviruses |volume=12 |issue=7 |pages=585–592 |pmid=8743084 |url= |accessdate= |quote= |doi=10.1089/aid.1996.12.585 |display-authors=1 |last2=Harrer |first2=Ellen |last3=Kalams |first3=Spyros A. |last4=Elbeik |first4=Tarek |last5=Staprans |first5=Silvija I. |last6=Feinberg |first6=Mark B. |last7=Cao |first7=Yunzhen |last8=Ho |first8=David D. |last9=Yilma |first9=Tilahun }}</ref> LTNP are not a homogeneous group regarding both viral load and specific immune responses against HIV-1. Some LTNPs are infected with HIV that inefficiently replicates<ref name=deacon>{{cite journal |last=Deacon |first=N.J. |authorlink=  |year=1995 |month= |title=Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients |journal=Science |volume=270 |issue=5238 |pages=988–991 |pmid=7481804 |url= |accessdate= |quote= |doi=10.1126/science.270.5238.988 |display-authors=1 |last2=Tsykin |first2=A. |last3=Solomon |first3=A. |last4=Smith |first4=K. |last5=Ludford-Menting |first5=M. |last6=Ellett |first6=A. |last7=Hooker |first7=D. J. |last8=McPhee |first8=D. A. |last9=Greenway |first9=A. L. }}</ref><ref name=kirchhoff>{{cite journal |last=Kirchhoff |first=F. |authorlink= |coauthors=T.C. Greenough, D.B. Brettler, J.L. Sullivan and R.C. Desrosiers |year=1995 |month= |title=Brief report: absence of intact nef sequences in a long-term survivor with nonprogressive HIV-1 infection |journal=New England Journal of Medicine |volume=332 |issue=4 |pages=228–232 |pmid=7808489 |url= |accessdate= |quote= |doi=10.1056/NEJM199501263320405 }}</ref> whilst others are infected with [[HIV]] that is virally fit and replicates normally, but the infected individual has had a strong and broad set of HIV-specific [[humoral]] and [[Cell-mediated immunity|cell-mediated response]]s that seems to delay the progression to AIDS. In some cohorts, individuals who experience signs of progression, but whose clinical and laboratory parameters remain stable over long periods of time, are classified as Long Term Survivors (LTS).<ref name=campbell/>

==Highly exposed persistently seronegative==
There is another, smaller percentage of individuals who have been recently identified. These are called Highly Exposed Persistently Seronegative (HEPS). This is a small group of individuals and has been observed only in a group of uninfected HIV-negative prostitutes in [[Kenya]] and in [[The Gambia]]. When these individuals' [[PBMC]]s are stimulated with HIV-1 peptides, they have [[lymphoproliferative]] activity and have HIV-1 specific CD8+ CTL activity suggesting that transient infection may have occurred.<ref name=clerici>{{cite journal |last=Clerici |first=M. |authorlink= |coauthors=J.M. Levin, H.A. Kessler, A. Harris, J.A. Berzofsky, A.L. Landay and G.M. Shearer |year=1994 |month= |title=HIV-specific T- helper activity in seronegative health care workers exposed to contaminated blood |journal=JAMA |volume=271 |issue=1 |pages=42–46 |pmid=8258885 |url= |accessdate= |quote= |doi=10.1001/jama.271.1.42 }}</ref><ref name=pinto>{{cite journal |last=Pinto |first=L.A. |authorlink= |coauthors=J. Sullivan, J.A. Berzofsky, M. Clerici, H.A. Kessler, A.L. Landay and G.M. Shearer |year=1995 |month= |title=ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids |journal=Journal of Clinical Investigation |volume=96 |issue=2 |pages=867–876 |pmid=7635981 |url= |accessdate= |quote= |doi=10.1172/JCI118133 |pmc=185273 }}</ref><ref name=Rowlandjones1995>{{cite journal |last=Rowland-Jones |first=S. |authorlink=  |year=1995 |month= |title=HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women |journal=Nature Medicine |volume=1 |issue=1 |pages=59–64 |pmid=7584954 |url= |accessdate= |quote= |doi=10.1038/nm0195-59 |display-authors=1 |last2=Sutton |first2=Julian |last3=Ariyoshi |first3=Koya |last4=Dong |first4=Tao |last5=Gotch |first5=Frances |last6=McAdam |first6=Steve |last7=Whitby |first7=Denise |last8=Sabally |first8=Sehu |last9=Gallimore |first9=Awen }}</ref><ref name=fowke>{{cite journal |last=Fowke |first=K.R. |authorlink=  |year=1996 |month= |title=Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya |journal=Lancet |volume=348 |issue=9038 |pages=1347–1351 |pmid=8918278 |url= |accessdate= |quote= |doi=10.1016/S0140-6736(95)12269-2 |display-authors=1 |last2=Nagelkerke |first2=N |last3=Kimani |first3=J |last4=Simonsen |first4=J |last5=Anzala |first5=A |last6=Bwayo |first6=J |last7=MacDonald |first7=K |last8=Ngugi |first8=E |last9=Plummer |first9=F }}</ref> This does not occur in unexposed individuals. What is interesting, is that the CTL epitope specificity differs between HEPS and HIV positive individuals, and in HEPS, the maintenance of responses appears to be dependent upon persistent exposure to HIV.<ref name=kaul>{{cite journal |last=Kaul |first=R. |authorlink=  |year=2001 |month= |title=New insights into HIV-1 specific cytotoxic T cell responses in exposed, persistently seronegative Kenyan sex workers |journal=Immunology Letters |volume=79 |issue=1–2 |pages=3–13 |pmid=11595284 |url= |accessdate= |quote= |doi=10.1016/S0165-2478(01)00260-7 |display-authors=1 |last2=Rowland-Jones |first2=Sarah L |last3=Kimani |first3=Joshua |last4=Fowke |first4=Keith |last5=Dong |first5=Tao |last6=Kiama |first6=Peter |last7=Rutherford |first7=John |last8=Njagi |first8=Ephantus |last9=Mwangi |first9=Francis }}</ref>

==Prediction of progression rates==
During the initial weeks after HIV infection, qualitative differences in the [[cell-mediated immune response]] are observed that correlate with different disease progression rates (i.e., rapid progression to [[WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents|WHO stage 4]] and the rapid loss of CD4+ T cell levels versus normal to slow progression to [[WHO Disease Staging System for HIV Infection and Disease in Adults and Adolescents|WHO stage 4]] and the maintenance of CD4+ T cell counts above 500/µl). The appearance of HIV-1-specific CD8+ cytotoxic [[T cell]]s (CTLs) early after primo-infection has been correlated with the control of HIV-1 viremia.<ref name=koup>{{cite journal |last=Koup |first=R.A. |authorlink= |coauthors=J.T. Safrit and Y.Z. Cao |year=1994 |month= |title=Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome |journal=Journal of Virology |volume=68 |issue=7 |pages=4650–4655 |pmid=8207839 |url= |accessdate= |quote= |pmc=236393 }}</ref><ref name=borrow1994>{{cite journal |last=Borrow |first=P. |authorlink= |coauthors=H. Lewicki, B.H. Hahn, G.M. Shaw and M.B. Oldstone |year=1994 |month= |title=Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection |journal=Journal of Virology |volume=68 |issue=9 |pages=6103–6110 |pmid=8057491 |url= |accessdate= |quote= |pmc=237022 }}</ref> The virus which escapes this CTL response have been found to have mutations in specific CTL epitopes.<ref name=phillips>{{cite journal |last=Phillips |first=R.E. |authorlink=  |year=1991 |month= |title=Human immunodeficiency virus genetic variation that can escape cytotoxic T cell recognition |journal=Nature |volume=354 |issue=6353 |pages=453–459 |pmid=1721107 |url= |accessdate= |quote= |doi=10.1038/354453a0 |display-authors=1 |last2=Rowland-Jones |first2=Sarah |last3=Nixon |first3=Douglas F. |last4=Gotch |first4=Frances M. |last5=Edwards |first5=Jon P. |last6=Ogunlesi |first6=Afolabi O. |last7=Elvin |first7=John G. |last8=Rothbard |first8=Jonathan A. |last9=Bangham |first9=Charles R. M. }}</ref><ref name=borrow1997>{{cite journal |last=Borrow |first=P. |authorlink=  |year=1997 |month= |title=Antiviral pressure exerted by HIV-1-specific cytotoxic T cells (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus |journal=Nature Medicine |volume=3 |issue=2 |pages=205–211 |pmid=9018240 |url= |accessdate= |quote= |doi=10.1038/nm0297-205 |display-authors=1 |last2=Lewicki |first2=Hanna |last3=Wei |first3=Xiping |last4=Horwitz |first4=Marc S. |last5=Peffer |first5=Nancy |last6=Meyers |first6=Heather |last7=Nelson |first7=Jay A. |last8=Gairin |first8=Jean Edouard |last9=Hahn |first9=Beatrice H. }}</ref><ref name=price>{{cite journal |last=Price |first=D.A. |authorlink= |coauthors=P.J. Goulder, P. Klenerman, A.K. Sewell, P.J. Easterbrook, M. Troop, C.R. Bangham and R.E. Phillips |year=1997 |month= |title=Positive selection of HIV-1 cytotoxic T lymphocyte escape variants during primary infection |journal=PNAS |volume=94 |issue=5 |pages=1890–1895 |pmid=9050875 |url= |accessdate= |quote= |doi=10.1073/pnas.94.5.1890 |pmc=20013 }}</ref><ref name=rowlandjones1992>{{cite journal |last=Rowland-Jones |first=S.L. |authorlink=  |year=1992 |month= |title=Human immunodeficiency virus variants that escape cytotoxic T-cell recognition |journal=AIDS Research and Human Retroviruses |volume=8 |issue=9 |pages=1353–1354 |pmid=1466955 |url= |accessdate= |quote= |display-authors=1 |last2=Phillips |first2=RE |last3=Nixon |first3=DF |last4=Gotch |first4=FM |last5=Edwards |first5=JP |last6=Ogunlesi |first6=AO |last7=Elvin |first7=JG |last8=Rothbard |first8=JA |last9=Bangham |first9=CR }}</ref> Individuals with a broad expansion of the V-beta chain of the T cell receptor of CD8+ T cells during primo-infection appear seem to have low levels of virus six to twelve months later, which is predictive of relatively slow disease progression. In contrast, individuals with an expansion of only a single subset of the V-beta chain of the CD8+ T cells are not able to control HIV levels over time, and thus have high levels of virus six to twelve months later.<ref name=pantalea>{{cite journal |last=Pantaleo |first=G. |authorlink=  |year=1997 |month= |title=The qualitative nature of the primary immune response to HIV infection is a prognosticator of disease progression independent of the initial level of plasma viremia |journal=PNAS |volume=94 |issue=1 |pages=254–258 |pmid=8990195 |url= |accessdate= |quote= |doi=10.1073/pnas.94.1.254 |pmc=19306 |display-authors=1 |last2=Demarest |first2=JF |last3=Schacker |first3=T |last4=Vaccarezza |first4=M |last5=Cohen |first5=OJ |last6=Daucher |first6=M |last7=Graziosi |first7=C |last8=Schnittman |first8=SS |last9=Quinn |first9=TC }}</ref> LTNP’s have also been shown to have a vigorous proliferation of circulating activated HIV-1-specific CD4+ T cell<ref name=rosenberg>{{cite journal |last=Rosenberg |first=E.S. |authorlink= |coauthors=J.M. Billingsley, A.M. Caliendo, S.L. Boswell, P.E. Sax, S.A. Kalams and B.D. Walker |year=1997 |month= |title=Vigorous HIV-1-specific CD4+ T cell responses associated with control of viremia |journal=Science |volume=278 |issue=5342 |pages=1447–1450 |pmid=9367954 |url= |accessdate= |quote= |doi=10.1126/science.278.5342.1447 }}</ref> and CTL response<ref name=rowlandjones1999>{{cite journal |last=Rowland-Jones |first=S.L. |authorlink=  |year=1999 |month= |title=Broadly cross-reactive HIV-specific cytotoxic T-lymphocytes in highly exposed persistently seronegative donors |journal=Immunology Letters |volume=66 |issue=1–3 |pages=9–14 |pmid=10203028 |url= |accessdate= |quote= |doi=10.1016/S0165-2478(98)00179-5 |display-authors=1 |last2=Dong |first2=T |last3=Dorrell |first3=L |last4=Ogg |first4=G |last5=Hansasuta |first5=P |last6=Krausa |first6=P |last7=Kimani |first7=J |last8=Sabally |first8=S |last9=Ariyoshi |first9=K }}</ref><ref name=dyer>{{cite journal |last=Dyer |first=W.B. |authorlink=  |year=199 |month= |title=Strong Human Immunodeficiency Virus (HIV)-Specific Cytotoxic T-Lymphocyte Activity in Sydney Blood Bank Cohort Patients Infected with nef-Defective HIV Type 1 |journal=Journal of Virology |volume=73 |issue=1 |pages=436–443 |pmid=9847349 |url= |accessdate= |quote= |pmc=103850 |display-authors=1 |last2=Ogg |first2=GS |last3=Demoitie |first3=MA |last4=Jin |first4=X |last5=Geczy |first5=AF |last6=Rowland-Jones |first6=SL |last7=McMichael |first7=AJ |last8=Nixon |first8=DF |last9=Sullivan |first9=JS }}</ref> against multiple [[epitope]]s with no detectable broadly cross-reactive [[neutralizing]] [[antibodies]] in the setting of an extremely low viral load.<ref name=harrer/> However, a few reports have correlated the presence of antibodies against [[Structure and genome of HIV#Genome organization|Tat]] in LTNP status.

==HIV subtype variation and effect on progression rates==
The HIV-1 subtype that an individual becomes infected with can be a major factor in the rate of progression from [[sero-conversion]] to AIDS. Individuals infected with subtypes C, D and G are 8 times more likely to develop [[AIDS]] than individuals infected with subtype A.<ref name=kanki>{{cite journal |last=Kanki |first=P.J. |authorlink=  |year=1999 |month= |title=Human immunodeficiency virus type 1 subtypes differ in disease progression |journal=Journal of Infectious Disease |volume=179 |issue=1 |pages=68–73 |pmid=9841824 |url= |accessdate= |quote= |doi=10.1086/314557 |display-authors=1 |last2=Hamel |first2=Donald J. |last3=Sankalé |first3=Jean‐Louis |last4=Hsieh |first4=Chung‐Cheng |last5=Thior |first5=Ibou |last6=Barin |first6=Francis |last7=Woodcock |first7=Stephen A. |last8=Guèye‐Ndiaye |first8=Aïssatou |last9=Zhang |first9=Er }}</ref> In [[Uganda]], where subtypes A and D are most prevalent,<ref name=kaleebu2000>{{cite journal |last=Kaleebu |first=P. |authorlink=  |year=2000 |month= |title=Molecular epidemiology of HIV type 1 in a rural community in southwest Uganda |journal=AIDS Research and Human Retroviruses |volume=16 |issue=5 |pages=393–401 |pmid=10772525 |url= |accessdate= |quote= |doi=10.1089/088922200309052 |display-authors=1 |last2=Orth |first2=James Whitw |last3=Hamilton |first3=Laura |last4=Rutebemberwa |first4=Alleluiah |last5=Lyagoba |first5=Fred |last6=Morgan |first6=Dilys |last7=Duffield |first7=Melanie |last8=Biryahwaho |first8=Benon |last9=Magambo |first9=Brian }}</ref> subtype D is associated with faster disease progression compared with subtype A.<ref name=kaleebu2002>{{cite journal |last=Kaleebu |first=P. |authorlink=  |year=2002 |month= |title=Effect of human immunodeficiency virus (HIV) type 1 envelope subtypes A and D on disease progression in a large cohort of HIV-1-positive persons in Uganda |journal=Journal of Infectious Disease |volume=185 |issue=9 |pages=1244–1250 |pmid=12001041 |url= |accessdate= |quote= |doi=10.1086/340130 |display-authors=1 |last2=French |first2=Neil |last3=Mahe |first3=Cedric |last4=Yirrell |first4=David |last5=Watera |first5=Christine |last6=Lyagoba |first6=Fred |last7=Nakiyingi |first7=Jessica |last8=Rutebemberwa |first8=Alleluiah |last9=Morgan |first9=Dilys }}</ref> [[senescence|Age]] has also been shown to be a major factor in determining survival and the rate of disease progression, with individuals over 40 years of age at sero-conversion being associated with rapid progression.<ref name=koblin>{{cite journal |last=Koblin |first=B.A. |authorlink=  |year=1999 |month= |title=Long-term survival after infection with human immunodeficiency virus type 1 (HIV-1) among homosexual men in hepatitis B vaccine trial cohorts in Amsterdam, New York City, and San Francisco, 1978-1995 |journal=American Journal of Epidemiology |volume=150 |issue=10 |pages=1026–1030 |pmid=10568617 |url= |accessdate= |quote= |display-authors=1 |last2=Van Benthem |first2=BH |last3=Buchbinder |first3=SP |last4=Ren |first4=L |last5=Vittinghoff |first5=E |last6=Stevens |first6=CE |last7=Coutinho |first7=RA |last8=Van Griensven |first8=GJ }}</ref><ref>{{cite journal |last=Pezzotti |first=P. |authorlink= |coauthors=N. Galai, D. Vlahov, G. Rezza, C.M. Lyles and J. Astemborski |year=1999 |month= |title=Direct comparison of time to AIDS and infectious disease death between HIV seroconverter injection drug users in Italy and the United States: results from the ALIVE and ISS studies. AIDS Link to Intravenous Experiences. Italian Seroconversion Study |journal=Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology |volume=20 |issue=3 |pages=275–282 |pmid=10077177 |url= |accessdate= |quote= |doi=10.1097/00042560-199903010-00010 }}</ref><ref name=collaborative>{{cite journal |last=Collaborative Group on AIDS Incubation and HIV Survival including the CASCADE EU Concerted Action. Concerted Action on SeroConversion to AIDS and Death in Europe |first= |authorlink= |coauthors= |year=2000 |month= |title=Time from HIV-1 seroconversion to AIDS and death before widespread use of highly active antiretroviral therapy: a collaborative re-analysis |journal=Lancet |volume=355 |issue= 9210|pages=1131–1137 |pmid= 10791375|url= |accessdate= |quote= |doi=10.1016/S0140-6736(00)02061-4 }}</ref><ref name=morgan1997>{{cite journal |last=Morgan |first=D. |authorlink= |coauthors=G.H. Maude, S.S. Malamba, M.J. Okongo, H.U. Wagner, D.W. Mulder and J.A. Whitworth |year=1997 |month= |title=HIV-1 disease progression and AIDS-defining disorders in rural Uganda |journal=Lancet |volume=350 |issue=9073 |pages=245–250 |pmid=9242801 |url= |accessdate= |quote= |doi=10.1016/S0140-6736(97)01474-8 }}</ref>

==Host genetic susceptibility==
The Centers for Disease Control and Prevention (CDC) has released findings that genes influence susceptibility to HIV infection and progression to AIDS. HIV enters cells through an interaction with both CD4 and a chemokine receptor of the [[7 transmembrane receptor|7 transmembrane]] family. They first reviewed the role of genes in encoding chemokine receptors ([[CCR5]] and [[CCR2]]) and chemokines (SDF-1). While CCR5 has multiple variants in its coding region, the deletion of a 32-bp segment results in a nonfunctional receptor, thus preventing HIV entry; two copies of this gene provide strong protection against HIV infection, although the protection is not absolute. This allele is found in around 10% of [[European ethnic groups|European]]s but is rare in [[Africans]] and [[Asians]]. Multiple studies of HIV-infected persons have shown that presence of one copy of this mutation, named [[CCR5-Δ32]] (CCR5 delta 32) delays progression to the condition of AIDS by about 2 years.

The [[National Institute of Health]] (NIH) has funded research studies to learn more about this [[genetic mutation]].  In such research, NIH has found that there exist genetic tests that can determine if a person has this mutation.  Implications of a genetic test may in the future allow clinicians to change treatment for the HIV infection according to the genetic makeup of an individual,<ref name=gonzalez>{{cite journal |last=Gonzalez |first=E. |authorlink=  |year=2005 |month= |title=The influence of CCL3L1 gene-containing segmental duplications on HIV-1/AIDS susceptibility |journal=Science |volume=307 |issue=5714 |pages=1422–1424 |pmid=15637236 |url= |accessdate= |quote= |doi=10.1126/science.1101160 |display-authors=1 |last2=James |first2=I |last3=Mallal |first3=S |last4=Mangano |first4=A |last5=Sanchez |first5=R |last6=Catano |first6=G |last7=Nibbs |first7=RJ |last8=Freedman |first8=BI |last9=Quinones |first9=MP }}</ref>  Currently there exist several at-home tests for the CCR5 mutation in individuals; however, they are not  diagnostic tests.

A relatively new class of drugs for HIV treatment relies on the genetic makeup of the individual.  [[Entry inhibitors]] bind to the CCR5 protein to block HIV from binding to the CD4 cell.

==The effect of co-infections on progression rates==
[[Coinfections]] or [[immunizations]] may enhance viral [[DNA replication|replication]] by inducing a response and activation of the immune system. This activation facilitates the three key stages of the [[viral life cycle]]: entry to the cell; reverse [[Transcription (genetics)|transcription]] and proviral transcription.<ref name=lawn>{{cite journal |last=Lawn |first=S.D. |authorlink= |coauthors=S.T. Butera and T.M. Folks |year=2001 |month= |title=Contribution of Immune Activation to the Pathogenesis and Transmission of Human Immunodeficiency Virus Type 1 Infection |journal=Clinical Microbiology Reviews |volume=14 |issue=4 |pages=753–777 |pmid=11585784 |url= |accessdate= |quote= |doi=10.1128/CMR.14.4.753-777.2001 |pmc=89002 }}</ref> [[Chemokine receptor]]s are vital for the entry of HIV into cells. The expression of these receptors is inducible by immune activation caused through infection or immunization, thus augmenting the number of cells that are able to be infected by HIV-1.<ref name=wahl>{{cite journal |last=Wahl |first=S.M. |authorlink= |coauthors=T. Greenwell-Wild, G. Peng, H. Hale-Donze, T.M. Doherty, D. Mizel and J.M. Orenstein |year=1998 |month= |title=Mycobacterium avium complex augments macrophage HIV-1 production and increases CCR5 expression |journal=PNAS |volume=95 |issue=21 |pages=12574–12579 |pmid=9770527 |url= |accessdate= |quote= |doi=10.1073/pnas.95.21.12574 |pmc=22872 }}</ref><ref name=juffermans>{{cite journal |last=Juffermans |first=N.P. |authorlink= |coauthors=P. Speelman, A. Verbon, J. Veenstra, C. Jie, S.J. van Deventer and T. van Der Poll |year=2001 |month= |title=Patients with active tuberculosis have increased expression of HIV coreceptors CXCR4 and CCR5 on CD4(+) T cells |journal=Clinical Infectious Diseases |volume=32 |issue=4 |pages=650–652 |pmid=11181132 |url= |accessdate= |quote= |doi=10.1086/318701 }}</ref> Both reverse transcription of the HIV-1 [[genome]] and the rate of transcription of proviral DNA rely upon the activation state of the cell and are less likely to be successful in quiescent cells. In activated cells there is an increase in the [[cytoplasm]]ic concentrations of mediators required for reverse transcription of the HIV genome.<ref name=zack>{{cite journal |last=Zack |first=J.A. |authorlink= |coauthors=S.J. Arrigo, S.R. Weitsman, A.S. Go, A. Haislip and I.S. Chen |year=1990 |month= |title=HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure |journal=Cell |volume=61 |issue=2 |pages=213–222 |pmid=2331748 |url= |accessdate= |quote= |doi=10.1016/0092-8674(90)90802-L }}</ref><ref name=kinoshita>{{cite journal |last=Kinoshita |first=S. |authorlink= |coauthors=B.K. Chen, H. Kaneshima and G.P. Nolan |year=1998 |month= |title=Host control of HIV-1 parasitism in T cells by the nuclear factor of activated T cells |journal=Cell |volume=95 |issue=5 |pages=595–604 |pmid=9845362 |url= |accessdate= |quote= |doi=10.1016/S0092-8674(00)81630-X }}</ref> Activated cells also release [[IFN]]-alpha which acts on an [[autocrine]] and [[paracrine]] loop that up-regulates the levels of physiologically active [[NF-kappa B]] which activates host cell genes as well as the HIV-1 LTR.<ref name=gaynor>{{cite journal |last=Gaynor |first=R. |authorlink= |coauthors= |year=1992 |month= |title=Cellular transcription factors involved in the regulation of HIV-1 gene expression |journal=AIDS |volume=6 |issue=4 |pages=347–363 |pmid=1616633 |url= |accessdate= |quote= |doi=10.1097/00002030-199204000-00001 }}</ref><ref name=baeuerle>{{cite journal |last=Baeuerle |first=P.A. |authorlink= |coauthors= |year=1991 |month= |title=The inducible transcription activator NF-kappa B: regulation by distinct protein subunits |journal=Biochimica et Biophysica Acta |volume=1072 |issue=1 |pages=63–80 |pmid=2018779 |url= |accessdate= |quote= }}</ref> The impact of co-infections by micro-organisms such as ''[[Mycobacterium tuberculosis]]'' can be important in disease progression, particularly for those who have a high prevalence of [[chronic (medicine)|chronic]] and recurrent [[acute (medical)|acute]] infections and poor access to medical care.<ref name=blanchard>{{cite journal |last=Blanchard |first=A. |authorlink= |coauthors=L. Montagnier and M.L. Gougeon |year=1997 |month= |title=Influence of microbial infections on the progression of HIV disease |journal=Trends in Microbiology |volume=5 |issue=8 |pages=326–331 |pmid=9263412 |url= |accessdate= |quote= |doi=10.1016/S0966-842X(97)01089-5 }}</ref> Often, survival depends upon the initial AIDS-defining illness.<ref name=morgan1997/> Co-infection with [[DNA]] [[virus]]es such as [[HTLV-1]], [[herpes simplex virus-2]], [[varicella zoster virus]] and [[cytomegalovirus]] may enhance [[proviral]] DNA transcription and thus viral load as they may encode [[protein]]s that are able to trans-activate the expression of the HIV-1 pro-viral DNA.<ref name=gendelman>{{cite journal |last=Gendelman |first=H.E. |authorlink=  |year=1986 |month= |title=Trans-activation of the human immunodeficiency virus long terminal repeat sequence by DNA viruses |journal=PNAS |volume=83 |issue=24 |pages=9759–9763 |pmid=2432602 |url= |accessdate= |quote= |doi=10.1073/pnas.83.24.9759 |pmc=387220 |display-authors=1 |last2=Phelps |first2=W |last3=Feigenbaum |first3=L |last4=Ostrove |first4=JM |last5=Adachi |first5=A |last6=Howley |first6=PM |last7=Khoury |first7=G |last8=Ginsberg |first8=HS |last9=Martin |first9=MA }}</ref> Frequent exposure to [[helminth]] infections, which are endemic in [[Africa]], activates individual [[immune system]]s, thereby shifting the [[cytokine]] balance away from an initial Th1 cell response against viruses and bacteria which would occur in the uninfected person to a less protective T helper 0/2-type response.<ref name=bentwich>{{cite journal |last=Bentwich |first=Z. |authorlink= |coauthors=A. Kalinkovich and Z. Weisman |year=1995 |month= |title=Immune activation is a dominant factor in the pathogenesis of African AIDS |journal=Immunology Today |volume=16 |issue=4 |pages=187–191 |pmid=7734046 |url= |accessdate= |quote= |doi=10.1016/0167-5699(95)80119-7 }}</ref> HIV-1 also promotes a Th1 to Th0 shift and replicates preferentially in Th2 and Th0 cells.<ref name=maggi>{{cite journal |last=Maggi |first=E. |authorlink=  |year=1994 |month= |title=Ability of HIV to promote a TH1 to TH0 shift and to replicate preferentially in TH2 and TH0 cells |journal=Science |volume=265 |issue=5169 |pages=244–248 |pmid=8023142 |url= |accessdate= |quote= |doi=10.1126/science.8023142 |display-authors=1 |last2=Mazzetti |first2=M |last3=Ravina |first3=A |last4=Annunziato |first4=F |last5=De Carli |first5=M |last6=Piccinni |first6=M. |last7=Manetti |first7=R |last8=Carbonari |first8=M |last9=Pesce |first9=A. }}</ref> This makes the host more susceptible to and less able to cope with infection with HIV-1,viruses and some types of bacteria.  Ironically, exposure to [[dengue]] virus seems to slow HIV progression rates temporarily.

==See also==
*[[CCR5]]

==References==
{{Reflist|2}}

==External links==
*{{cite news |first=Nicholas |last=Wade |title=Gene Variation May Raise Risk of H.I.V., Study Finds |url=http://www.nytimes.com/2008/07/17/science/17hiv.html |work= |publisher=New York Times |date=July 18, 2008 |accessdate=2008-09-06 }}

{{AIDS}}

[[Category:HIV/AIDS]]